ReviewMetabolites2020
Metabolomic Profiling in the Characterization of Degenerative Bone and Joint Diseases.
Review in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Consequences of Aging on Bone.Aging and disease · 2023Pooled it
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
- Surface marker-defined functional subpopulations of mesenchymal stromal cells: mechanisms, applications, and clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- Changes in frailty and incident risk of degenerative bone and joint diseases and their multimorbidity: a prospective cohort study.Frontiers in public health · 2026Article
- Metabolic signatures in osteoporotic cancellous bone: a comprehensive dual-platform metabolomic analysis.BMC musculoskeletal disorders · 2025Article
- Current cutting-edge omics techniques on musculoskeletal tissues and diseases.Bone research · 2025Review
- AI-Assisted Plasmonic Diagnostics Platform for Osteoarthritis and Rheumatoid Arthritis With Biomarker Quantification Using Mathematical Models.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Analysis of Key Differential Metabolites in Intervertebral Disc Degeneration Based on Untargeted Metabolomics.JOR spine · 2025Article
- Osteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis.Metabolites · 2025Article
- Integrated proteomics and metabolomics analysis of sclerosis-related proteins and femoral head necrosis following internal fixation of femoral neck fractures.Scientific reports · 2024Article
- Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification.Molecules (Basel, Switzerland) · 2024Review
- Myricetin Protects Against Rat Intervertebral Disc Degeneration Partly Through the Nrf2/HO-1/NF-κB Signaling Pathway.Biochemical genetics · 2024Article
- Changes in the Serum Metabolome in an Inflammatory Model of Osteoarthritis in Rats.International journal of molecular sciences · 2024Article
- Metabolic profiling of synovial fluid in human temporomandibular joint osteoarthritis.Frontiers in immunology · 2024Article
- Biomarkers for intervertebral disc and associated back pain: From diagnosis to disease prognosis and personalized treatment.JOR spine · 2023Review
- WouldJournal of personalized medicine · 2023Article
- Discovery of potential biomarkers for osteoporosis using LC/GC-MS metabolomic methods.Frontiers in endocrinology · 2023Article
- Modulation of the biological network of lumbar spinal stenosis by Tongdu Huoxue Decoction based on clinical metabolomics.Frontiers in molecular biosciences · 2023Article
- Article
- Integration of metabolomics and transcriptomics provides insights into enhanced osteogenesis inFrontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis and inflammatory arthropathies are a cause of significant morbidity globally. New research elucidating the metabolic derangements associated with a variety of bone and joint disorders implicates various local and systemic metabolites, which further elucidate the underlying molecular mechanisms associated with these destructive disease processes. In osteoarthritis, atty acid metabolism has been implicated in disease development, both locally and systemically. Several series of rheumatoid arthritis patients have demonstrated overlapping trends related to histidine and glyceric acid, while other series showed similar results of increased cholesterol and glutamic acid. Studies comparing osteoarthritis and rheumatoid arthritis reported elevated gluconic acid and glycolytic- and tricarboxylic acid-related substrates in patients with osteoarthritis, while lysosphingolipids and cardiolipins were elevated only in patients with rheumatoid arthritis. Other bone and joint disorders, including osteonecrosis, intervertebral disc degeneration, and osteoporosis, also showed significant alterations in metabolic processes. The identification of the molecular mechanisms of osteoarthritis and inflammatory arthropathies via metabolomics-based workflows may allow for the development of new therapeutic targets to improve the quality of life in these patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.